首页 | 本学科首页   官方微博 | 高级检索  
     

重组人血管内皮抑制素对大鼠放射性心肌纤维化的影响
引用本文:旷华香,徐世林,欧阳伟炜,赵朝芬,李晓阳,陈霞霞,杨文刚,马筑,卢冰,苏胜发. 重组人血管内皮抑制素对大鼠放射性心肌纤维化的影响[J]. 中华放射医学与防护杂志, 2020, 40(5): 343-348
作者姓名:旷华香  徐世林  欧阳伟炜  赵朝芬  李晓阳  陈霞霞  杨文刚  马筑  卢冰  苏胜发
作者单位:苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004,苏胜发 贵州医科大学附属医院肿瘤科 贵州医科大学肿瘤学教研室 贵州省肿瘤医院肿瘤科, 贵阳 550004
基金项目:国家自然科学基金(81660507);贵州省科技支撑计划项目([2018]2755)
摘    要:
目的 建立放射性心脏纤维化大鼠模型,观察重组人血管内皮抑制素(恩度)对心肌纤维化的影响,初探转化生长因子-β1(TGF-β1)、结缔组织生长因子(CTGF)与心肌纤维化的相关性。方法 将40只SD大鼠按随机数表法分为4组,每组10只,A组为健康对照组;B组为恩度干预组,恩度(6 mg/kg)腹腔连续注射14 d;C组为单纯照射组,心脏照射25 Gy/5次,连续5 d;D组为照射+恩度干预组,恩度给药方法同B组、心脏照射方法同C组。照射后第1、3个月各麻醉处死5只大鼠。Masson染色评估心肌纤维化情况,Western blot检测心肌TGF-β1、CTGF及胶原蛋白Ⅰ(COL-Ⅰ)型表达。结果 照射后1和3个月,B组未见明显的心肌纤维化表现,C组和D组可见胶原纤维分布于心肌细胞间质。照射后1个月,半定量分析结果显示A组的心肌胶原容积分数(CVF)为(5.20±0.75)%,C组(10.12±2.17)%和D组(10.32±1.36)均高于A组(t=4.74、4.93,P<0.01),C组和D组的CVF差异无统计学意义(P>0.05);照射后3个月C组的CVF(13.17±2.67)%仍比A组(5.23±1.32)%高(t=4.49,P<0.01),C组的CVF低于D组(16.92±3.58)%(t=3.19,P<0.05)。照射后1个月,A组TGF-β1的表达量为0.441±0.063,C组0.817±0.079高于A组(t=5.81,P<0.01);照射后3个月,A组TGF-β1的表达量为0.501±0.110,C组0.832±0.150高于A组(t=4.19,P<0.01),D组1.403±0.133高于C组(t=7.24,P<0.01)。照射后1、3个月,各组间CTGF及COL-I的变化趋势与TGF-β1的变化趋势相似。结论 射线可引起心肌纤维化的形成,重组人血管内皮抑制素可能会加重晚期放射纤维化的形成。

关 键 词:重组人血管内皮抑制素  放射  心脏  纤维化
收稿时间:2019-09-13

Recombinant human endostatin reduces radiation-induced myocardial fibrosis in rats
Kuang Huaxiang,Xu Shilin,Ouyang Weiwei,Zhao Chaofen,Li Xiaoyang,Chen Xiaxi,Yang Wengang,Ma Zhu,Lu Bing and Su Shengfa. Recombinant human endostatin reduces radiation-induced myocardial fibrosis in rats[J]. Chinese Journal of Radiological Medicine and Protection, 2020, 40(5): 343-348
Authors:Kuang Huaxiang  Xu Shilin  Ouyang Weiwei  Zhao Chaofen  Li Xiaoyang  Chen Xiaxi  Yang Wengang  Ma Zhu  Lu Bing  Su Shengfa
Affiliation:Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China,Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China,Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China,Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China,Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China,Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China,Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China,Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China,Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China and Department of Oncology, Affiliated Hospital of Guizhou Medical University, Teaching and Research Section of Oncology, Guizhou Medical University, Department of Oncology, Guizhou Cancer Hospital, Guiyang 550004, China
Abstract:
Keywords:Recombinant human endostatin  Radiation  Heart  Fibrosis
点击此处可从《中华放射医学与防护杂志》浏览原始摘要信息
点击此处可从《中华放射医学与防护杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号